EDIT Editas Medicine, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1650664 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.4%
TTM net income YoY63.9%
TTM EPS YoY77.0%
Revenue 3-yr CAGR26.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-151.7%
Net margin-145.0%
FCF margin-221.7%
EBITDA margin-147.5%
Returns
ROE-147.4%
ROA-34.3%
ROIC (approx.)—
Asset turnover0.24x
Leverage & solvency
Liabilities / assets61.5%
Debt / equity0.67x
Current ratio2.82x
Interest coverage-10.58x
Cash quality & payout
Operating cash flow / net income1.53x
Accruals ratio18.0%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.37M | $11.89M | $2.83M | $24.74M | $7.54M | $3.58M | $4.66M | $30.60M |
| R&D expense | $21.17M | $20.18M | $17.60M | $27.40M | $19.77M | $16.18M | $26.59M | $48.61M |
| SG&A expense | $13.48M | $11.60M | $10.23M | $11.35M | $12.32M | $12.86M | $13.38M | $16.35M |
| Operating income | -$24.28M | -$18.55M | -$25.00M | -$7.75M | -$24.55M | -$51.54M | -$76.16M | -$46.59M |
| Interest expense | $1.08M | $1.06M | $5.00M | $0 | $2.40M | $2.02M | $2.13M | $2.13M |
| Net income | -$23.39M | -$18.23M | -$24.98M | -$5.62M | -$25.12M | -$53.23M | -$76.09M | -$45.40M |
| EBITDA | -$23.90M | -$18.14M | -$24.52M | -$6.95M | -$23.83M | -$49.71M | -$74.25M | -$45.21M |
| EPS (basic) | -0.15 | -0.15 | -0.26 | — | -0.28 | -0.63 | -0.92 | — |
| EPS (diluted) | -0.15 | -0.15 | -0.26 | — | -0.28 | -0.63 | -0.92 | — |
| Weighted avg. shares (diluted) | 153.60M | 119.29M | 97.88M | — | 90.09M | 84.41M | 83.06M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $93.17M | $181.81M | $123.65M | $146.65M | $165.65M | $138.54M | $138.69M | $135.42M |
| Short-term investments | $97.03M | $29.83M | — | $0 | $0 | $39.96M | $82.27M | $138.37M |
| Receivables | $7.73M | $2.73M | $2.59M | $15.18M | $8.13M | $588,000 | $510,000 | $16.27M |
| Current assets | $201.97M | $218.07M | $128.07M | $163.90M | $176.89M | $182.80M | $224.84M | $289.31M |
| PP&E, net | $2.19M | $2.57M | $2.88M | $3.54M | $4.29M | $4.58M | $8.18M | $14.50M |
| Total assets | $219.41M | $237.36M | $149.34M | $186.53M | $201.75M | $210.58M | $263.65M | $341.59M |
| Current liabilities | $71.58M | $68.43M | $39.78M | $46.25M | $61.77M | $65.94M | $73.11M | $77.22M |
| Short-term debt | $7.50M | $7.50M | $7.50M | $5.00M | $5.00M | $5.00M | $5.00M | $5.00M |
| Long-term debt | $49.32M | $48.24M | $47.18M | $53.60M | $54.07M | $51.67M | $49.58M | $52.43M |
| Total debt | $56.82M | $55.74M | $54.68M | $58.60M | $59.07M | $56.67M | $54.58M | $57.43M |
| Total liabilities | $134.89M | $132.08M | $144.93M | $159.25M | $188.30M | $191.39M | $201.23M | $207.31M |
| Shareholders' equity | $84.52M | $105.28M | $4.41M | $27.29M | $13.45M | $19.19M | $62.42M | $134.27M |
| Net debt | -$36.35M | -$126.08M | -$68.97M | -$88.04M | -$106.58M | -$81.87M | -$84.11M | -$77.98M |
| Shares outstanding | 97.87M | 97.87M | 97.87M | 97.87M | 93.26M | 87.39M | 83.71M | 82.73M |
| Cash flow statement | ||||||||
| Operating cash flow | -$21.19M | -$29.57M | -$23.06M | -$36.39M | -$30.84M | -$50.21M | -$47.80M | -$50.76M |
| Capital expenditure | $0 | $106,000 | $92,000 | $60,000 | $433,000 | $0 | $114,000 | $540,000 |
| Free cash flow | -$21.19M | -$29.67M | -$23.15M | -$36.45M | -$31.28M | -$50.21M | -$47.91M | -$51.30M |
| Investing cash flow | -$66.99M | -$29.80M | $64,000 | $58,000 | $39.57M | $42.65M | $56.39M | $30.96M |
| Financing cash flow | -$468,000 | $117.53M | $0 | $17.33M | $17.17M | $7.41M | -$1.44M | $55.51M |
| Depreciation & amortization | $385,000 | $416,000 | $483,000 | $805,000 | $721,000 | $1.83M | $1.92M | $1.38M |
| Stock-based compensation | $2.57M | $2.19M | $2.10M | $2.13M | $2.23M | $2.66M | $2.98M | $4.02M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.